Jaguar Health, Inc.: Jaguar Health Announces Submission of Investigational New Drug Application to FDA for Drug Candidate for the Symptomatic Relief of Diarrhea from Cholera

Jaguar is concentrating financial and management resources on two near-term late-stage clinical eventsSAN FRANCISCO, CA / ACCESSWIRE / August 30, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the

Related Keywords

Italy ,Yemen ,Bangladesh ,Milan ,Lombardia ,Dubai ,Dubayy ,United Arab Emirates ,United States ,Italian ,Lisa Conte ,Steven King ,Peter Hodge ,Jaguar Health Inc ,National Institute Of Allergy ,Napo Therapeutics Jaguar Animal Health ,Nasdaq ,Us Department Of Health Human Services ,Napo Pharmaceuticals Inc ,Centers For Disease ,Jaguar Health ,Drug Administration For Napo ,National Institutes Of Health ,Jaguar Animal Health ,Napo Pharmaceuticals ,International Centre For Diarrhoeal Disease Research ,Ethnobotanical Research Ip Officer ,Investigational New Drug ,Drug Administration ,Chief Sustainable Supply ,Ethnobotanical Research ,International Centre ,Diarrhoeal Disease Research ,Tropical Disease Priority Review Voucher ,Streeterville Capital ,National Institute ,Infectious Diseases ,National Institutes ,Disease Control ,Napo Therapeutics ,Jaguar Animal ,Jaguar ,Health ,Nnounces ,Submission ,Investigational ,Drug ,Application ,Candidate ,Asymptomatic ,Relief ,Diarrhea ,Rom ,Cholera ,